SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 603.16 |
| Enterprise Value ($M) | 554.43 |
| Book Value ($M) | 97.37 |
| Book Value / Share | 0.51 |
| Price / Book | 6.02 |
| NCAV ($M) | 92.97 |
| NCAV / Share | 0.49 |
| Price / NCAV | 6.49 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.68 |
| Return on Assets (ROA) | -0.47 |
| Return on Equity (ROE) | -0.61 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.15 |
| Current Ratio | 8.15 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 127.32 |
| Assets | 131.71 |
| Liabilities | 34.34 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 6.17 |
| Operating Income | -73.69 |
| Net Income | -69.92 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -64.85 |
| Cash from Investing | 22.95 |
| Cash from Financing | 52.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Roivant Sciences Ltd. | 20.50 | 0.00 | |
| 13D/A | Whitefort Capital Master Fund, LP | 7.00 | ||
| 13G/A | Morgan Stanley | 11.40 | 10.99 | |
| 13G/A | Two Seas Capital LP | 4.40 | -7.24 | |
| 13D/A | Whitefort Capital Management, LP | 6.80 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 102,383 | 658,945 | 15.54 | |
| 289,699 | 1,018,041 | 28.46 | |
| 357,963 | 992,974 | 36.05 | |
| 233,958 | 1,018,007 | 22.98 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABCL – AbCellera Biologics Inc. | ABOS – Acumen Pharmaceuticals, Inc. |
| ACAD – ACADIA Pharmaceuticals Inc. | ACLX – Arcellx, Inc. |